0001140361-11-048592.txt : 20111006 0001140361-11-048592.hdr.sgml : 20111006 20111006132320 ACCESSION NUMBER: 0001140361-11-048592 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20111004 FILED AS OF DATE: 20111006 DATE AS OF CHANGE: 20111006 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: AYERS JONATHAN W CENTRAL INDEX KEY: 0001184149 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19271 FILM NUMBER: 111128803 MAIL ADDRESS: STREET 1: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IDEXX LABORATORIES INC /DE CENTRAL INDEX KEY: 0000874716 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 010393723 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092-2041 BUSINESS PHONE: 2075560300 MAIL ADDRESS: STREET 1: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092-2041 FORMER COMPANY: FORMER CONFORMED NAME: IDEXX CORP / DE DATE OF NAME CHANGE: 19600201 4 1 doc1.xml FORM 4 X0304 4 2011-10-04 0 0000874716 IDEXX LABORATORIES INC /DE IDXX 0001184149 AYERS JONATHAN W ONE IDEXX DRIVE WESTBROOK ME 04092 1 1 0 0 CHAIRMAN, PRESIDENT & CEO Common Stock 2011-10-04 4 M 0 20000 12.6 A 317697 D Common Stock 2011-10-04 4 S 0 9500 64.2054 D 308197 D Common Stock 2011-10-04 4 S 0 5500 64.5939 D 302697 D Common Stock 2011-10-05 4 M 0 20000 12.6 A 322697 D Common Stock 2011-10-05 4 S 0 14597 66.1209 D 308100 D Common Stock 2011-10-05 4 S 0 403 66.7387 D 307697 D Non-Qualified Stock Option (right to buy) 12.60 2011-10-04 4 M 0 20000 0 D 2012-01-28 Common Stock 20000 100320 D Non-Qualified Stock Option (right to buy) 12.6 2011-10-05 4 M 0 20000 0 D 2012-01-28 Common Stock 20000 80320 D Includes 79 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 09/30/2011. The reported sale above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 03/03/2011. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $63.88 to $64.85, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3, 4, 5 and 6 to this Form 4. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $65.00 to $65.43, inclusive. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $65.66 to $66.57, inclusive. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $66.69 to $66.75, inclusive. Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (01/28/2003) of the date of grant. Conan R. Deady, Attorney-in-Fact for Jonathan W. Ayers 2011-10-06